Not all antihistamines hit the brain the same way, older imaging research suggests

What happened

An explainer, as first reported by Medical Xpress (Medical Xpress), makes a point worth knowing before your next allergy flare: antihistamines differ a lot in how much they affect your brain.

The piece says some can cause sleepiness, slower reactions and poorer concentration, while others are much less likely to. It also says that even people who feel only a little tired may be reacting more slowly than they realize.

This is not a new trial. We could not identify a single study behind the item, and our notes come from an excerpt of it. It leans on older brain-imaging, performance and review research, which we checked against the underlying papers below.

What the research actually found

The core idea is receptor occupancy. Reviews attribute first-generation sedation to drugs that dissolve easily in fat and slip across the blood-brain barrier, while second-generation drugs are far less likely to get in (PubMed). One review reports that PET imaging with a [11C]-doxepin tracer showed first-generation drugs occupying more than 70% of H1 receptors in the central nervous system (PMC).

A PET-based classification turns that into three bands (PMC, PMC).

Dose matters: cetirizine slides from the first band to the second when the dose doubles. In one PET study, d-chlorpheniramine showed 76.8% occupancy (PMC).

Fexofenadine is an outlier on the good side. It is a strong substrate of a pump (P-glycoprotein) that pushes it out of the brain, and one review calls it devoid of central nervous system effects. The same review says many other second-generation drugs still enter the brain slightly and can cause some drowsiness, especially at higher doses (PMC).

Performance data point the same way. In a comparative trial described in a review, diphenhydramine caused significant deficits in divided attention, working memory, vigilance and speed, while loratadine performed like placebo. The review adds that first-generation effects can linger into the next day, even after a dose the night before (PubMed).

What it does not show

Occupancy is a stand-in. How many receptors a drug binds in a scan is not the same as how sleepy you feel at 2 p.m. or how you handle a left turn.

• There is no single new study here, and the cited literature is largely older.
• We did not capture sample sizes for the PET or performance studies, so we cannot tell you how large or varied those groups were.
• Individual response varies. Cetirizine is the standard example of a second-generation drug that makes some people drowsy, usually less than older drugs, according to the explainer.
• We did not review current FDA or MHRA labeling on drowsiness and driving, or allergy-society guidelines, so check your own product label.

What it means for you

If you need to be sharp for work or the road, newer-generation drugs are the usual starting point. One review describes second-generation drugs as first-line for allergic disease and says first-generation drugs are not recommended for it (PubMed).

A few cautious habits follow from the evidence:

• Stay at the labeled dose. One review says cetirizine and loratadine can cause sedation when recommended doses are exceeded (PMC).
• Try a new antihistamine when you do not have to drive or make important decisions, and see how you feel.
• Do not trust your own sense of being fine. A driving review says people may miss or underestimate the central nervous system effects of these drugs, and that blurred vision and dilated pupils can also affect driving (PMC).
• Treat a bedtime sedating dose with care. Next-day effects were reported even after night-before dosing.
• Untreated symptoms count too. A 1997 abstract says allergic rhinitis itself causes decision-making and psychomotor deficits, which sedating drugs make worse (PubMed).

Some people do find the sedating effect useful, as the explainer notes. If that is you, a pharmacist can help you choose with the next-morning cost in mind.

Context: the dementia headlines

The explainer mentions research on anticholinergic effects and brain health, and a related-links headline claims some antihistamines may increase dementia risk (Medical Xpress). That headline overreaches. The study behind it measured delirium in hospitalized older adults, not dementia.

It analyzed 328,140 patients aged 65 or older admitted by 755 attending physicians at 17 Ontario hospitals from 2015 to 2022. Delirium prevalence was 34.8%. Patients of physicians who prescribed more first-generation antihistamines had 41% higher odds of delirium than patients of physicians who rarely did (EurekAlert).

The exposure was the doctor's prescribing rate, not each patient's own dose, and the design is observational, so it cannot show cause.

On dementia itself, a separate Medical Xpress explainer calls the link uncertain. It says prolonged first-generation use is associated with higher risk, but the evidence does not support the same for second-generation drugs (Medical Xpress). An NEJM Clinician summary of about 120,000 adults aged 50 or older found no increase in new-onset dementia over 5 years with any antihistamine versus steroids, though its own takeaway was that the evidence is not totally reassuring for second-generation drugs (NEJM Clinician).